首页 > 最新文献

Clinical and Experimental Vaccine Research最新文献

英文 中文
Factors associated with side effects of COVID-19 vaccine in Indonesia 印度尼西亚与COVID-19疫苗副作用相关的因素
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.89
J. Wibowo, R. Heriyanto, F. Wijovi, D. A. Halim, C. Claudia, E. Marcella, B. Susanto, Michele Indrawan, Nadia Khoirunnisa Heryadi, Michelle Imanuelly, Jonathan Juniard Anurantha, T. Hariyanto, C.P.G.P.P. Marcellin, Terry Devita Sinaga, Saraswati Anindita Rizki, N. Sieto, J. Siregar, N. Lugito, A. Kurniawan
Purpose As coronavirus disease 2019 (COVID-19) continues to spread rapidly causing approximately 186 million confirmed cases around the world, the urgency to reach herd immunity through vaccination is increasing. However, vaccine safety is a top priority to limit the occurrence of adverse events. Henceforth, this study aims to recognize and perceive COVID-19 vaccine safety in Indonesia during the pandemic. Materials and Methods This is a cross-sectional study and was conducted in Indonesia during the COVID-19 pandemic using an online survey of demographic information and a qualitative questionnaire. Responses were recorded and the association between demographic characteristics from survey questions was tested using chi-square with a risk estimate and 95% confidence interval. Results A total of 311 participants from 33 out of 34 provinces in Indonesia participated in this study. Recorded responses showed multiple side effects of the COVID-19 vaccine both short- and long-term experienced by the participants. Significant associations were found between demographic factors and COVID-19 vaccine side effects such as female gender with short-term puncture site (odds ratio [OR], 0.463; 95% confidence interval [CI], 0.263–0.816) and short-term other reactions (OR, 0.463; 95% CI, 0.263–0.816), domicile outside Java island with long-term puncture site (OR, 4.219; 95% CI, 1.401–12.701) and immune reactions (OR, 3.375; 95% CI, 1.356–8.398), also between married marital status and long-term vagal reaction (OR, 4.655; 95% CI, 1.321–16.409). Conclusion Gender, domicile and marital status factors were associated with COVID-19 vaccine side effects in Indonesian people.
随着2019冠状病毒病(COVID-19)继续迅速传播,在全球造成约1.86亿确诊病例,通过疫苗接种实现群体免疫的紧迫性日益增加。然而,疫苗安全性是限制不良事件发生的首要任务。因此,本研究的目的是在大流行期间认识和感知印度尼西亚的COVID-19疫苗安全性。材料和方法这是一项横断面研究,于2019冠状病毒病大流行期间在印度尼西亚进行,采用在线人口统计信息调查和定性问卷。对应答进行记录,并使用带有风险估计值和95%置信区间的卡方检验调查问题中人口学特征之间的关联。结果来自印尼34个省中的33个省共311名受试者参与了本研究。记录的反应显示,参与者经历了COVID-19疫苗的多种短期和长期副作用。人口统计学因素与COVID-19疫苗副作用有显著相关性,如女性性别与短期穿刺部位(优势比[OR], 0.463;95%可信区间[CI], 0.263-0.816)和短期其他反应(OR, 0.463;95% CI, 0.263-0.816),居住在爪哇岛以外,有长期穿刺部位(OR, 4.219;95% CI, 1.401-12.701)和免疫反应(OR, 3.375;95% CI, 1.356-8.398),婚姻状况与长期迷走神经反应之间也存在差异(OR, 4.655;95% ci, 1.321-16.409)。结论性别、户籍和婚姻状况因素与印尼人群COVID-19疫苗副作用相关。
{"title":"Factors associated with side effects of COVID-19 vaccine in Indonesia","authors":"J. Wibowo, R. Heriyanto, F. Wijovi, D. A. Halim, C. Claudia, E. Marcella, B. Susanto, Michele Indrawan, Nadia Khoirunnisa Heryadi, Michelle Imanuelly, Jonathan Juniard Anurantha, T. Hariyanto, C.P.G.P.P. Marcellin, Terry Devita Sinaga, Saraswati Anindita Rizki, N. Sieto, J. Siregar, N. Lugito, A. Kurniawan","doi":"10.7774/cevr.2022.11.1.89","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.89","url":null,"abstract":"Purpose As coronavirus disease 2019 (COVID-19) continues to spread rapidly causing approximately 186 million confirmed cases around the world, the urgency to reach herd immunity through vaccination is increasing. However, vaccine safety is a top priority to limit the occurrence of adverse events. Henceforth, this study aims to recognize and perceive COVID-19 vaccine safety in Indonesia during the pandemic. Materials and Methods This is a cross-sectional study and was conducted in Indonesia during the COVID-19 pandemic using an online survey of demographic information and a qualitative questionnaire. Responses were recorded and the association between demographic characteristics from survey questions was tested using chi-square with a risk estimate and 95% confidence interval. Results A total of 311 participants from 33 out of 34 provinces in Indonesia participated in this study. Recorded responses showed multiple side effects of the COVID-19 vaccine both short- and long-term experienced by the participants. Significant associations were found between demographic factors and COVID-19 vaccine side effects such as female gender with short-term puncture site (odds ratio [OR], 0.463; 95% confidence interval [CI], 0.263–0.816) and short-term other reactions (OR, 0.463; 95% CI, 0.263–0.816), domicile outside Java island with long-term puncture site (OR, 4.219; 95% CI, 1.401–12.701) and immune reactions (OR, 3.375; 95% CI, 1.356–8.398), also between married marital status and long-term vagal reaction (OR, 4.655; 95% CI, 1.321–16.409). Conclusion Gender, domicile and marital status factors were associated with COVID-19 vaccine side effects in Indonesian people.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"89 - 95"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46645747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Successful seroconversion against diphtheria and tetanus induced through maternal vaccination in a region of Colombia 哥伦比亚某地区通过母体疫苗接种成功实现白喉和破伤风血清转换
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.72
D. Hincapié-Palacio, Adriana Echeverri, Cristina Hoyos, Felipe Vargas-Restrepo, Marta Ospina, Seti Buitrago, J. Ochoa
Purpose This study aims to compare protection against diphtheria and tetanus conferred on the mother and the neonate before and after maternal vaccination against tetanus, diphtheria, and acellular pertussis (Tdap), transfer of antibodies, and the variables that could impact on the protection. Materials and Methods The study followed a cohort of 200 pregnant women from a region in Colombia, contacted during prenatal control before vaccination and upon delivery. The work determined immunoglobulin G antibodies against diphtheria and tetanus of pregnant women and umbilical cord. The proportion of protection, the geometric mean of the concentration, and the transfer of maternal antibodies were calculated. The protection profile of the pregnant women was explored by using multiple correspondence analysis. Results The concentration of antibodies against diphtheria was significant before and after vaccination of the pregnant women (p=0.000) with proportions of 85.0% and 97.5%, respectively, and of 98.6% in the umbilical cord, with significant antibody correlation (Spearman’s coefficient=0.668, p=0.01). Sero-protection against tetanus before vaccination was at 71.0%, after at 92.6%, and in the umbilical cord at 95.9%, with significant antibody concentration before and after vaccination (p=0.000) and antibody correlation (Spearman’s coefficient=0.936, p=0.01). Sero-protection was higher when the pregnant women were vaccine 8 to 11 weeks before delivery. Unprotected pregnant women were those not vaccinated during pregnancy. Conclusion The high proportion of protection against diphtheria and tetanus and the placental transfer support the need to promote maternal immunization with Tdap.
目的本研究旨在比较母亲和新生儿在接种破伤风、白喉和无细胞百日咳疫苗前后对白喉和破伤风的保护作用、抗体的转移以及可能影响保护作用的变量。材料和方法这项研究跟踪了来自哥伦比亚一个地区的200名孕妇,她们在接种疫苗前和分娩时进行了产前控制。这项工作测定了孕妇和脐带的白喉和破伤风免疫球蛋白G抗体。计算保护比例、浓度的几何平均值和母体抗体的转移。采用多重对应分析法对孕妇的保护状况进行了探讨。结果孕妇接种白喉疫苗前后白喉抗体浓度显著(p=0.000),在脐带中的比例分别为85.0%和97.5%,抗体相关性显著(Spearman系数=0.668,p=0.01),在脐带中为95.9%,接种前后抗体浓度显著(p=0.000),抗体相关性显著(Spearman系数=0.936,p=0.01)。孕妇在分娩前8至11周接种疫苗时血清保护作用更高。未接种疫苗的孕妇是那些在怀孕期间没有接种疫苗的妇女。结论高比例的白喉、破伤风防护和胎盘转移支持了提高孕妇Tdap免疫的必要性。
{"title":"Successful seroconversion against diphtheria and tetanus induced through maternal vaccination in a region of Colombia","authors":"D. Hincapié-Palacio, Adriana Echeverri, Cristina Hoyos, Felipe Vargas-Restrepo, Marta Ospina, Seti Buitrago, J. Ochoa","doi":"10.7774/cevr.2022.11.1.72","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.72","url":null,"abstract":"Purpose This study aims to compare protection against diphtheria and tetanus conferred on the mother and the neonate before and after maternal vaccination against tetanus, diphtheria, and acellular pertussis (Tdap), transfer of antibodies, and the variables that could impact on the protection. Materials and Methods The study followed a cohort of 200 pregnant women from a region in Colombia, contacted during prenatal control before vaccination and upon delivery. The work determined immunoglobulin G antibodies against diphtheria and tetanus of pregnant women and umbilical cord. The proportion of protection, the geometric mean of the concentration, and the transfer of maternal antibodies were calculated. The protection profile of the pregnant women was explored by using multiple correspondence analysis. Results The concentration of antibodies against diphtheria was significant before and after vaccination of the pregnant women (p=0.000) with proportions of 85.0% and 97.5%, respectively, and of 98.6% in the umbilical cord, with significant antibody correlation (Spearman’s coefficient=0.668, p=0.01). Sero-protection against tetanus before vaccination was at 71.0%, after at 92.6%, and in the umbilical cord at 95.9%, with significant antibody concentration before and after vaccination (p=0.000) and antibody correlation (Spearman’s coefficient=0.936, p=0.01). Sero-protection was higher when the pregnant women were vaccine 8 to 11 weeks before delivery. Unprotected pregnant women were those not vaccinated during pregnancy. Conclusion The high proportion of protection against diphtheria and tetanus and the placental transfer support the need to promote maternal immunization with Tdap.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"72 - 81"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42673636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia 与印度尼西亚乙型肝炎(Bio-Farma)疫苗相比,不同批量来源的重组乙型肝炎疫苗的保护性和安全性
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.43
Yetty M Nency, F. A. Rahmadi, Mulyono, D. T. Anantyo, Nurain Farhanah, Rebriarina Hapsari, H. Farida, U. Sadhana, Herry Djagat, T. Kristina, A. Juniarto, Mita Puspita, Rini Mulia Sari, N. Bachtiar
Purpose Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both the national immunization program and global needs. To keep the sustainability of the vaccine, a new bulk is needed to be made available. This study aims to evaluate the immunogenicity and safety of Bio Farma newly formulated recombinant hepatitis B vaccines, which came from different sources of bulk, compared to the already registered hepatitis B vaccine. Materials and Methods An experimental, randomized, double-blind, cohort intervention phase II clinical trial was conducted on three recombinant hepatitis B vaccines from different bulk sources, with Bio Farma registered hepatitis B vaccine as the control group. A total of 536 participants around age 10 to 40 years old were thricely vaccinated with twice serological assessments. The subject’s safety was monitored for 28 days after each vaccination. Results Of 536 enrolled participants, 521 finished the vaccination and serology assessments. The investigational products were proven not to be inferior to the control. All vaccines were well tolerated. No differences in rates of local and systemic reactions were seen between the investigational products and control. No serious adverse event was found to be related to the investigational vaccines. Conclusion Investigational vaccines are shown to be equally immunogenic and safe as the control vaccine.
目的印度尼西亚是东南亚人口众多、乙型肝炎流行率第二高的国家,需要保持其单价乙型肝炎生产能力,以满足国家免疫计划和全球需求。为了保持疫苗的可持续性,需要提供新的疫苗。本研究旨在评估Bio-Farma新配制的重组乙型肝炎疫苗的免疫原性和安全性,与已注册的乙型肝炎疫苗相比,该疫苗来自不同的批量来源。材料与方法以Bio-Farma注册的乙肝疫苗为对照组,对三种不同来源的重组乙肝疫苗进行实验性、随机、双盲、队列干预的II期临床试验。共有536名年龄在10至40岁之间的参与者接种了三次疫苗,并进行了两次血清学评估。受试者的安全性在每次接种疫苗后监测28天。结果536名参与者中,521人完成了疫苗接种和血清学评估。试验药物被证明不劣于对照品。所有疫苗都具有良好的耐受性。研究药物和对照组的局部和全身反应发生率没有差异。未发现与试验疫苗有关的严重不良事件。结论研究性疫苗与对照疫苗具有同等的免疫原性和安全性。
{"title":"Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia","authors":"Yetty M Nency, F. A. Rahmadi, Mulyono, D. T. Anantyo, Nurain Farhanah, Rebriarina Hapsari, H. Farida, U. Sadhana, Herry Djagat, T. Kristina, A. Juniarto, Mita Puspita, Rini Mulia Sari, N. Bachtiar","doi":"10.7774/cevr.2022.11.1.43","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.43","url":null,"abstract":"Purpose Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both the national immunization program and global needs. To keep the sustainability of the vaccine, a new bulk is needed to be made available. This study aims to evaluate the immunogenicity and safety of Bio Farma newly formulated recombinant hepatitis B vaccines, which came from different sources of bulk, compared to the already registered hepatitis B vaccine. Materials and Methods An experimental, randomized, double-blind, cohort intervention phase II clinical trial was conducted on three recombinant hepatitis B vaccines from different bulk sources, with Bio Farma registered hepatitis B vaccine as the control group. A total of 536 participants around age 10 to 40 years old were thricely vaccinated with twice serological assessments. The subject’s safety was monitored for 28 days after each vaccination. Results Of 536 enrolled participants, 521 finished the vaccination and serology assessments. The investigational products were proven not to be inferior to the control. All vaccines were well tolerated. No differences in rates of local and systemic reactions were seen between the investigational products and control. No serious adverse event was found to be related to the investigational vaccines. Conclusion Investigational vaccines are shown to be equally immunogenic and safe as the control vaccine.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"43 - 52"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42723223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels 骆驼产气荚膜梭状芽孢杆菌和牛病毒性腹泻联合疫苗的制备及现场研究
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.30
H. Elhelw, Maha Raafat Abd el Fadeel, E. El-Sergany, A. Allam, M. K. Elbayoumy, A. El-Kattan, A. A. El-Kholy
Purpose The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels’ calves against these infectious pathogens under field conditions. Materials and Methods The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.
目的本研究的主要目的是研制一种含有牛病毒性腹泻病毒(BVDV)-1、BVDV-2和产气荚膜梭菌a型类毒素的局部联合灭活凝胶佐剂疫苗。该研究评估了其在野外条件下增强骆驼幼崽对这些传染性病原体的保护性主动免疫反应的能力。材料与方法采用BVDV细胞病变株和产毒产气荚膜梭菌a型的地方株进行疫苗配制。疫苗A和B分别是针对产气荚膜梭菌和两种BVDV菌株的单价疫苗。而疫苗C是针对这三种药物使用的联合疫苗。所有的疫苗都用Montanide凝胶作为佐剂。对配制的疫苗进行了无菌性、安全性和效力测试。病毒中和试验和毒素-毒素-抗毒素中和试验用于评估免疫反应。结果从接种后第2周起,单价疫苗(疫苗A)和联合疫苗(疫苗C)对产气荚膜梭菌的保护水平分别为4.5和3IU/mL。接种后第5个月,滴度分别降至3和2 IU/mL。单价疫苗(疫苗B)对BVDV-1a和BVDV-2的抗BVDV滴度分别在接种后1个月达到喙部(1.95 IU/mL)和持续到接种后6个月(0.92和0.94 IU/mL)。结论建议采用含产气荚膜梭菌A型类毒素和BVDV株的Montanide凝胶联合疫苗,间隔6个月对骆驼进行接种,以安全有效地保护骆驼免受此类感染。
{"title":"Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels","authors":"H. Elhelw, Maha Raafat Abd el Fadeel, E. El-Sergany, A. Allam, M. K. Elbayoumy, A. El-Kattan, A. A. El-Kholy","doi":"10.7774/cevr.2022.11.1.30","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.30","url":null,"abstract":"Purpose The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels’ calves against these infectious pathogens under field conditions. Materials and Methods The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"30 - 42"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49551602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Knowledge, attitude, and practices regarding human papillomavirus and its’ vaccination among the young medical professionals and students of Bangladesh 孟加拉国年轻医疗专业人员和学生关于人乳头瘤病毒及其疫苗接种的知识、态度和做法
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.63
Sreshtha Chowdhury, R. Ara, Simanta Roy, Syed Md Sayeem Tanvir, Fahima Nasrin Eva, Tasnova Mehrin Neela, Amena Akter Moonmoon, Shamma Sifat, Mushfera Zamila, M. D. Hawlader
Purpose Sexually transmitted infections are a major worldwide concern, and human papillomavirus (HPV) is one of the significant risk factors. Many populations suffer from various diseases caused by HPV, and the overall death toll due to cervical carcinoma is remarkable. Despite vaccine availability, perception about vaccine safety and efficacy, its’ preventive outcome is still inferior among the health professionals and vaccine providers. So, this study aims to assess the knowledge, attitude, and practice level of HPV and its’ vaccination among doctors, dentists, and medical students. Materials and Methods This cross-sectional survey was carried out between April to August 2021, where 626 participants from all types of medical institutions of Bangladesh were interviewed using a validated and structured questionnaire that consists of four extensive areas; socio-demographic characteristics, HPV knowledge, attitude, and practices regarding vaccination. Results The knowledge and practice standards showed very poor outcomes where 43.29% of the participants showed good knowledge and only 11.82% conveyed good practices. Nevertheless, the attitude towards HPV vaccination was revealed high (75.88%). Female participants showed more positive attitudes than males. Conclusion Physicians and dentists play vital roles in raising public knowledge about HPV and awareness regarding HPV vaccination programs. The provision of medical education on HPV must be prioritized, and current training techniques must be re-evaluated. Thus, by implementing this strategy, improvement in national vaccination policy can be expected.
目的性传播感染是世界范围内关注的主要问题,人乳头瘤病毒(HPV)是重要的危险因素之一。许多人群患有由HPV引起的各种疾病,宫颈癌造成的总死亡人数是显著的。尽管疫苗可用,人们对疫苗的安全性和有效性有看法,但其预防效果在卫生专业人员和疫苗供应商中仍然较差。因此,本研究旨在评估医生、牙医和医学生对HPV及其疫苗接种的知识、态度和实践水平。材料和方法这项横断面调查于2021年4月至8月进行,来自孟加拉国所有类型医疗机构的626名参与者使用经验证的结构化问卷进行了访谈,问卷由四个广泛领域组成;社会人口学特征、HPV知识、态度和疫苗接种实践。结果知识和实践标准的结果非常差,43.29%的参与者表现出良好的知识,只有11.82%的参与者传达了良好的实践。然而,对HPV疫苗接种的态度很高(75.88%)。女性参与者表现出比男性更积极的态度。结论医生和牙医在提高公众对HPV的认识和对HPV疫苗接种计划的认识方面发挥着重要作用。必须优先提供关于HPV的医学教育,并且必须重新评估当前的培训技术。因此,通过实施这一战略,国家疫苗接种政策有望得到改善。
{"title":"Knowledge, attitude, and practices regarding human papillomavirus and its’ vaccination among the young medical professionals and students of Bangladesh","authors":"Sreshtha Chowdhury, R. Ara, Simanta Roy, Syed Md Sayeem Tanvir, Fahima Nasrin Eva, Tasnova Mehrin Neela, Amena Akter Moonmoon, Shamma Sifat, Mushfera Zamila, M. D. Hawlader","doi":"10.7774/cevr.2022.11.1.63","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.63","url":null,"abstract":"Purpose Sexually transmitted infections are a major worldwide concern, and human papillomavirus (HPV) is one of the significant risk factors. Many populations suffer from various diseases caused by HPV, and the overall death toll due to cervical carcinoma is remarkable. Despite vaccine availability, perception about vaccine safety and efficacy, its’ preventive outcome is still inferior among the health professionals and vaccine providers. So, this study aims to assess the knowledge, attitude, and practice level of HPV and its’ vaccination among doctors, dentists, and medical students. Materials and Methods This cross-sectional survey was carried out between April to August 2021, where 626 participants from all types of medical institutions of Bangladesh were interviewed using a validated and structured questionnaire that consists of four extensive areas; socio-demographic characteristics, HPV knowledge, attitude, and practices regarding vaccination. Results The knowledge and practice standards showed very poor outcomes where 43.29% of the participants showed good knowledge and only 11.82% conveyed good practices. Nevertheless, the attitude towards HPV vaccination was revealed high (75.88%). Female participants showed more positive attitudes than males. Conclusion Physicians and dentists play vital roles in raising public knowledge about HPV and awareness regarding HPV vaccination programs. The provision of medical education on HPV must be prioritized, and current training techniques must be re-evaluated. Thus, by implementing this strategy, improvement in national vaccination policy can be expected.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"63 - 71"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46870045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults 印度尼西亚成人冠状病毒疫苗抗sars - cov -2受体结合域抗体的评价
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.116
Juandy Jo, Astia Sanjaya, R. Pinontoan, Maroloan Aruan, R. M. Wahyuni, Venansi Viktaria
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
在学术场所调查了CoronaVac在印度尼西亚成人中的免疫原性。两剂CoronaVac疫苗对抗SARS-CoV-2受体结合域(RBD)抗体滴度在9.1 ~ 151.9 U/mL之间的成人(SARS-CoV-2) naïve诱导完全血清转化。中位数低于2019年轻度冠状病毒病康复成人的中位数(38.7对114.5 U/mL)。尽管如此,93.6%的接种成人,与76.5%的恢复成人相比,显示出高于临界值的抑制率,以阻止rbd -血管紧张素转换酶2的结合。这表明,两剂冠状病毒疫苗具有免疫原性,可能对印度尼西亚成年人有保护作用。
{"title":"Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults","authors":"Juandy Jo, Astia Sanjaya, R. Pinontoan, Maroloan Aruan, R. M. Wahyuni, Venansi Viktaria","doi":"10.7774/cevr.2022.11.1.116","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.116","url":null,"abstract":"The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"116 - 120"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43073393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The risk of confusion between AstraZeneka COVID-19 vaccine side effects and signs of COVID-19 infection: a case report 阿斯利康新冠肺炎疫苗副作用与新冠肺炎感染迹象之间混淆的风险:一份病例报告
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.125
M. Nomali, Mahdieh Afzali
Post-vaccination side effects of AstraZeneca (AZ) coronavirus disease 2019 (COVID-19) vaccine are common. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection immediately after the first dose of AZ COVID-19 vaccine has not been reported. In this case, a 30-year-old female without a past medical history of SARS-CoV2 infection presented to an outpatient clinic with lightheadedness and weakness 2 hours after getting the first dose of the AZ COVID-19 vaccine. Blood pressure (BP) was 80/60 mm Hg, and oxygen saturation (SpO2) was 98%. After administering normal saline intravenous fluid, the BP was 110/80 mm Hg. On the first day, fever (oral temperature of 39℃), sweating, dry cough, sore throat, and injection-site pain were presented. On the second day, diarrhea, productive cough, and hypotension occurred in addition to fever (oral temperature of 39.9℃). The fever did not stop and productive cough, change in smell, and fatigue were reported. SpO2 was 96%. On the third day, no abnormality of the spiral lung computed tomography and the positive reverse transcriptase-polymerase chain reaction (RT-PCR) test were reported. Simultaneously, two out of three members of the family became symptomatic on the second day and their RT-PCR tests were positive. Dexamethasone ampule, Cefixime tablet, Acetaminophen tablet, and Diphenhydramine syrup were prescribed. After a week, fever subsided and SpO2 was 98%. After 3 weeks of self-quarantine at home, her general condition improved. Despite the similarity between SARS-CoV2 infection signs and symptoms and AZ COVID-19 vaccine side effects, none of the approved vaccines contain the live virus that causes disease. Therefore, any unusual post-vaccination signs and symptoms should not be attributed to the vaccine itself and need to be considered for further evaluations and early actions in order to prevent the spread of the disease in society.
阿斯利康(AZ)2019冠状病毒病(新冠肺炎)疫苗接种后的副作用很常见。尚未报告首次接种AZ新冠肺炎疫苗后立即感染严重急性呼吸综合征冠状病毒2型(SARS-CoV2)。在这种情况下,一名30岁的女性在接种第一剂AZ新冠肺炎疫苗2小时后出现头晕和虚弱症状,既往无SARS-CoV2感染史。血压(BP)为80/60毫米汞柱,血氧饱和度(SpO2)为98%。在给予生理盐水静脉输液后,血压为110/80mm Hg。第一天出现发烧(口腔温度39℃)、出汗、干咳、喉咙痛和注射部位疼痛。第二天,除了发烧(口腔温度39.9℃)外,还出现腹泻、生产性咳嗽和低血压。发烧没有停止,并报告了生产性咳嗽、嗅觉变化和疲劳。SpO2为96%。第三天,螺旋肺计算机断层扫描和逆转录聚合酶链式反应(RT-PCR)阳性检测均未报告异常。与此同时,该家庭三分之二的成员在第二天出现症状,他们的RT-PCR检测呈阳性。处方包括地塞米松安瓿、头孢克肟片、对乙酰氨基酚片和苯海拉明糖浆。一周后,发烧消退,血氧饱和度为98%。在家自我隔离3周后,她的总体情况有所好转。尽管SARS-CoV2感染体征和症状与AZ新冠肺炎疫苗副作用相似,但没有一种获批疫苗含有导致疾病的活病毒。因此,任何不寻常的疫苗接种后体征和症状都不应归因于疫苗本身,需要考虑进行进一步评估和早期行动,以防止疾病在社会中传播。
{"title":"The risk of confusion between AstraZeneka COVID-19 vaccine side effects and signs of COVID-19 infection: a case report","authors":"M. Nomali, Mahdieh Afzali","doi":"10.7774/cevr.2022.11.1.125","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.125","url":null,"abstract":"Post-vaccination side effects of AstraZeneca (AZ) coronavirus disease 2019 (COVID-19) vaccine are common. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection immediately after the first dose of AZ COVID-19 vaccine has not been reported. In this case, a 30-year-old female without a past medical history of SARS-CoV2 infection presented to an outpatient clinic with lightheadedness and weakness 2 hours after getting the first dose of the AZ COVID-19 vaccine. Blood pressure (BP) was 80/60 mm Hg, and oxygen saturation (SpO2) was 98%. After administering normal saline intravenous fluid, the BP was 110/80 mm Hg. On the first day, fever (oral temperature of 39℃), sweating, dry cough, sore throat, and injection-site pain were presented. On the second day, diarrhea, productive cough, and hypotension occurred in addition to fever (oral temperature of 39.9℃). The fever did not stop and productive cough, change in smell, and fatigue were reported. SpO2 was 96%. On the third day, no abnormality of the spiral lung computed tomography and the positive reverse transcriptase-polymerase chain reaction (RT-PCR) test were reported. Simultaneously, two out of three members of the family became symptomatic on the second day and their RT-PCR tests were positive. Dexamethasone ampule, Cefixime tablet, Acetaminophen tablet, and Diphenhydramine syrup were prescribed. After a week, fever subsided and SpO2 was 98%. After 3 weeks of self-quarantine at home, her general condition improved. Despite the similarity between SARS-CoV2 infection signs and symptoms and AZ COVID-19 vaccine side effects, none of the approved vaccines contain the live virus that causes disease. Therefore, any unusual post-vaccination signs and symptoms should not be attributed to the vaccine itself and need to be considered for further evaluations and early actions in order to prevent the spread of the disease in society.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"125 - 128"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45241744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison and efficacy of two different sheep pox vaccines prepared from the Bakırköy strain against lumpy skin disease in cattle Bakırköy株制备的两种不同羊痘疫苗对牛块状皮肤病的疗效比较
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.1
S. Uzar, F. Sarac, V. Gulyaz, Hakan Enul, H. Yılmaz, N. Turan
Purpose Lumpy skin disease (LSD) is a highly contagious and economically important viral infection of cattle, which leads to financial losses in the livestock industry of affected countries. Vaccination is the most effective control measure to prevent the disease. Heterologous sheep pox (SP) vaccine was used against LSD in Turkey. In this research, it was aimed to adapt SP Bakırköy vaccine strain attenuated in lamb kidney cells to Madin-Darby bovine kidney (MDBK) cells to provide better protection than commercial SP vaccine in cattle. Materials and Methods To evaluate safety and efficacy of vaccines, while animals were immunized with 10 doses (104.75 50% tissue culture infectious dose [TCID50]) and 5 doses of SP vaccine (104 TCID50) produced in MDBK cells, others were immunized with commercial Penpox-M vaccine (103.9 TCID50). Two cattle were kept as unvaccinated. At day 31 post-vaccination, all animals were challenged with the virulent LSD virus. Blood and swab samples were taken on certain days post-inoculation. Logarithmic differences challenge virus titers between vaccinated and unvaccinated animals were calculated. Results The clinical sign was not observed in animals immunized with 10 doses of SP vaccine. The differences between the animals immunized with SP vaccine and control group was less than log 2.5 and the viremia occurred in immunized animals. The difference in titer was higher than log 2.5 in animals immunized with the Penpox-M, and viremia did not occur. Conclusion SP vaccine strain propagated in MDBK cells and can be used for immunization to prevent LSD infections. However, SP vaccine strain propagated in MDBK showed poor protection as compared to Penpox-M.
目的块状皮肤病(LSD)是一种高度传染性和经济上重要的牛病毒感染,它会导致受影响国家畜牧业的经济损失。接种疫苗是预防这种疾病最有效的控制措施。土耳其使用异源羊痘(SP)疫苗对抗LSD。在这项研究中,其目的是将在羊肾细胞中减毒的SP Bakırköy疫苗株适应Madin-Darby牛肾(MDBK)细胞,以在牛中提供比商业SP疫苗更好的保护。材料与方法为评价疫苗的安全性和有效性,用MDBK细胞制备的10剂(104.75 50%组织培养感染剂[TCID50])和5剂SP疫苗(104 TCID50)免疫动物,其他动物用市售Penpox-M疫苗(103.9 TCID 50)免疫。饲养了两头未接种疫苗的牛。在接种疫苗后第31天,所有动物都受到LSD病毒的攻击。在接种后的某些日子采集血液和拭子样本。计算接种疫苗和未接种疫苗的动物之间的挑战性病毒滴度的对数差异。结果10剂SP疫苗免疫动物未出现临床症状。用SP疫苗免疫的动物与对照组之间的差异小于log2.5,并且在免疫的动物中出现病毒血症。在用Penpox-M免疫的动物中,滴度的差异高于log2.5,并且没有发生病毒血症。结论SP疫苗株在MDBK细胞中繁殖,可用于预防LSD感染。然而,与Penpox-M相比,在MDBK中繁殖的SP疫苗株显示出较差的保护作用。
{"title":"Comparison and efficacy of two different sheep pox vaccines prepared from the Bakırköy strain against lumpy skin disease in cattle","authors":"S. Uzar, F. Sarac, V. Gulyaz, Hakan Enul, H. Yılmaz, N. Turan","doi":"10.7774/cevr.2022.11.1.1","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.1","url":null,"abstract":"Purpose Lumpy skin disease (LSD) is a highly contagious and economically important viral infection of cattle, which leads to financial losses in the livestock industry of affected countries. Vaccination is the most effective control measure to prevent the disease. Heterologous sheep pox (SP) vaccine was used against LSD in Turkey. In this research, it was aimed to adapt SP Bakırköy vaccine strain attenuated in lamb kidney cells to Madin-Darby bovine kidney (MDBK) cells to provide better protection than commercial SP vaccine in cattle. Materials and Methods To evaluate safety and efficacy of vaccines, while animals were immunized with 10 doses (104.75 50% tissue culture infectious dose [TCID50]) and 5 doses of SP vaccine (104 TCID50) produced in MDBK cells, others were immunized with commercial Penpox-M vaccine (103.9 TCID50). Two cattle were kept as unvaccinated. At day 31 post-vaccination, all animals were challenged with the virulent LSD virus. Blood and swab samples were taken on certain days post-inoculation. Logarithmic differences challenge virus titers between vaccinated and unvaccinated animals were calculated. Results The clinical sign was not observed in animals immunized with 10 doses of SP vaccine. The differences between the animals immunized with SP vaccine and control group was less than log 2.5 and the viremia occurred in immunized animals. The difference in titer was higher than log 2.5 in animals immunized with the Penpox-M, and viremia did not occur. Conclusion SP vaccine strain propagated in MDBK cells and can be used for immunization to prevent LSD infections. However, SP vaccine strain propagated in MDBK showed poor protection as compared to Penpox-M.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"1 - 11"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47133636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production 非洲COVID-19疫苗开发:对疫苗生产现状和现有挑战的审查
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2022-01-01 DOI: 10.7774/cevr.2022.11.1.82
E. Lamptey, E. Senkyire, Dooshima Aki Benita, E. Boakye
Following the development of the coronavirus disease 2019 (COVID-19) vaccines and the launching of vaccination, the World Health Organization has reported that the African Continent is lagging in the race to vaccinate its population against the deadly virus. The Continent has received a limited number of vaccines, implying that vaccine production needs to be scaled up in Africa. In this review, we summarize the current situation concerning COVID-19 vaccine development in Africa, progress made, challenges faced in vaccine development over the years and potential strategies that will harness vaccine production success.
随着2019冠状病毒病(新冠肺炎)疫苗的开发和疫苗接种的启动,世界卫生组织报告称,非洲大陆在为其人口接种致命病毒疫苗的竞赛中落后。非洲大陆收到的疫苗数量有限,这意味着非洲需要扩大疫苗生产。在这篇综述中,我们总结了非洲新冠肺炎疫苗开发的现状、取得的进展、多年来疫苗开发面临的挑战以及利用疫苗生产成功的潜在战略。
{"title":"COVID-19 vaccines development in Africa: a review of current situation and existing challenges of vaccine production","authors":"E. Lamptey, E. Senkyire, Dooshima Aki Benita, E. Boakye","doi":"10.7774/cevr.2022.11.1.82","DOIUrl":"https://doi.org/10.7774/cevr.2022.11.1.82","url":null,"abstract":"Following the development of the coronavirus disease 2019 (COVID-19) vaccines and the launching of vaccination, the World Health Organization has reported that the African Continent is lagging in the race to vaccinate its population against the deadly virus. The Continent has received a limited number of vaccines, implying that vaccine production needs to be scaled up in Africa. In this review, we summarize the current situation concerning COVID-19 vaccine development in Africa, progress made, challenges faced in vaccine development over the years and potential strategies that will harness vaccine production success.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"11 1","pages":"82 - 88"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44518621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Shingles and mRNA COVID-19 vaccine. 带状疱疹和mRNA COVID-19疫苗。
IF 2.7 Q4 IMMUNOLOGY Pub Date : 2021-09-01 Epub Date: 2021-09-30 DOI: 10.7774/cevr.2021.10.3.292
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
{"title":"Shingles and mRNA COVID-19 vaccine.","authors":"Rujittika Mungmunpuntipantip, Viroj Wiwanitkit","doi":"10.7774/cevr.2021.10.3.292","DOIUrl":"https://doi.org/10.7774/cevr.2021.10.3.292","url":null,"abstract":"","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"10 3","pages":"292"},"PeriodicalIF":2.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/29/cevr-10-292.PMC8511590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39564374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Vaccine Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1